Abstract
Background: The problem of bacterial resistance of Mycobacterium tuberculosis should be solved by seeking for alternative substances that potentially inhibit the growth or kill the bacteria. Ganoderma lucidum is one type of fungus which is potential to be an antimicrobial agent. This study aimed to determine the potential of G. lucidum on inhibiting the growth of multidrug-resistant bacteria of M. tuberculosis in vitro.
Methods: This study used a solid dilution method to test the extract of G. lucidum as an antibacterial agent.
Results and Conclusion: Results showed that all strains of multidrug-resistant tuberculosis (MDR-Tb) gave similar responses to G. lucidum extract at various concentrations. The bacteria did not grow on the medium containing G. lucidum extract at the smallest concentration of 12.5%, as well as concentrations of 25% and 50%. Ganoderma lucidum can be used as one of the alternatives for MDR-Tb drugs in the future.
Keywords: Antibacterial agent, Ganoderma lucidum, Mycobacterium tuberculosis, resistance, MDR-Tb, antimicrobialagents.
Anti-Infective Agents
Title:The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis
Volume: 16 Issue: 1
Author(s): Meira Erawati*, Megah Andriany and Niken Safitri Dyan Kusumaningrum
Affiliation:
- Faculty of Medicine, Diponegoro University, Semarang,Indonesia
Keywords: Antibacterial agent, Ganoderma lucidum, Mycobacterium tuberculosis, resistance, MDR-Tb, antimicrobialagents.
Abstract: Background: The problem of bacterial resistance of Mycobacterium tuberculosis should be solved by seeking for alternative substances that potentially inhibit the growth or kill the bacteria. Ganoderma lucidum is one type of fungus which is potential to be an antimicrobial agent. This study aimed to determine the potential of G. lucidum on inhibiting the growth of multidrug-resistant bacteria of M. tuberculosis in vitro.
Methods: This study used a solid dilution method to test the extract of G. lucidum as an antibacterial agent.
Results and Conclusion: Results showed that all strains of multidrug-resistant tuberculosis (MDR-Tb) gave similar responses to G. lucidum extract at various concentrations. The bacteria did not grow on the medium containing G. lucidum extract at the smallest concentration of 12.5%, as well as concentrations of 25% and 50%. Ganoderma lucidum can be used as one of the alternatives for MDR-Tb drugs in the future.
Export Options
About this article
Cite this article as:
Erawati Meira *, Andriany Megah and Kusumaningrum Safitri Dyan Niken , The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis, Anti-Infective Agents 2018; 16 (1) . https://dx.doi.org/10.2174/2211352516666180227135043
DOI https://dx.doi.org/10.2174/2211352516666180227135043 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Based Design of Inhibitors of the Crucial Cysteine Biosynthetic Pathway Enzyme O-Acetyl Serine Sulfhydrylase
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Antimycobacterial Agents: Synthesis and Biological Evaluation of Novel 4-(Substituted-phenyl)-6-methyl-2-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine- 5-carboxamide Derivatives by Using One-pot Multicomponent Method
Letters in Drug Design & Discovery Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology Anti-Inflammatory and Analgesic Activity of Methanolic and Hydro- Alcoholic Extract of Myrsine africana L. Fruits
The Natural Products Journal Editorial: [A Threat to One is a Threat to All – Biosecurity for the Western World Starts in Developing Countries: Do We Speak the Same Language of Hygiene?]
Inflammation & Allergy - Drug Targets (Discontinued) Meet Our Editorial Board Member:
Current HIV Research Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives
Letters in Drug Design & Discovery Development of Novel Nano Niosomes As Drug Delivery System of <i>Spermacoce hispida</i> Extract and <i>In Vitro</i> Antituberculosis Activity
Current Nanomaterials Fragment Based Drug Design: From Experimental to Computational Approaches
Current Medicinal Chemistry Distinction Between Esterases and Lipases: Comparative Biochemical Properties of Sequence-Related Carboxylesterases
Protein & Peptide Letters Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets An Overview of the Antimicrobial Activity of Polymeric Nanoparticles Against Enterobacteriaceae
Current Pharmaceutical Design Prevention and Management of SARS-CoV-2 Infection Among the Health Care Workers
Coronaviruses Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Overexpression and Characterization of the C-Terminal Domain of Human SIVA1: A Proapoptotic Factor and Cytoskeleton Binding Protein
Protein & Peptide Letters Recent Advances in the Development of Small-Molecular Inhibitors Target HIV Integrase-LEDGF/p75 Interaction
Mini-Reviews in Medicinal Chemistry Itraconazole vs Fluconazole as a Primary Prophylaxis for Fungal Infections in HIV-Infected Patients in Thailand
Current HIV Research Tartrate-Resistant Acid Phosphatase: A Target for Anti-Osteoporotic Chemotherapeutics
Current Enzyme Inhibition